Delta-Fly Pharma Inc Ordinary Shares 4598
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 4598 is a good fit for your portfolio.
News
-
Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax
-
Delta-Fly Pharma Inc.: FDA submission of the protocol of the Phase I/II study of DFP-10917 combined with Venetoclax (VTX) in the AML patients pretreated by VTX involved one regimen
-
Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting
-
Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323
Trading Information
- Previous Close Price
- JPY 805.00
- Day Range
- JPY 799.00–817.00
- 52-Week Range
- JPY 763.00–1,825.00
- Bid/Ask
- JPY 805.00 / JPY 812.00
- Market Cap
- JPY 6.68 Bil
- Volume/Avg
- 67,900 / 161,988
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Delta-Fly Pharma Inc is a Japan-based company mainly engaged in the discovery and development of gentle anti-cancer agents with module technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 11
- Website
- http://www.delta-flypharma.co.jp
Valuation
Metric
|
4598
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.99 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
4598
|
---|---|
Quick Ratio | 18.99 |
Current Ratio | 19.12 |
Interest Coverage | — |
Quick Ratio
4598
Profitability
Metric
|
4598
|
---|---|
Return on Assets (Normalized) | −128.19% |
Return on Equity (Normalized) | −144.72% |
Return on Invested Capital (Normalized) | −141.79% |
Return on Assets
4598
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xlnvtmnb | Wqs | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ysqqrrm | Dwsnrt | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ddtjtpxcg | Jqqhyj | $98.8 Bil | |
MRNA
| Moderna Inc | Qnscwmdz | Zmcw | $38.8 Bil | |
ARGX
| argenx SE ADR | Mmzllgcjq | Nycj | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Mnbvsmnl | Mrt | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gxlbpvjz | Vkwbpsp | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ltyxqmdc | Nzyzdd | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rllysdbm | Qfbbfsl | $12.4 Bil | |
INCY
| Incyte Corp | Hjpwpqrf | Ntqfzxf | $11.9 Bil |